EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Effectiveness of standard treatments in non-small-cell lung cancer with METexon14 skipping mutation: a real-world study

Muhammad Furqan iD, Siddharth Karanth iD, Ravi K Goyal iD, Beilei Cai iD, Julien Rombi, Keith L Davis iD, Nydia Caro, Teddy Saliba

Future Oncology · 2024

DOI: 10.2217/fon-2023-1064 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Future Oncology, 2024. Verfasst von Muhammad Furqan und 7 weiteren Autor:innen. Beteiligte Einrichtung: University of Iowa Hospitals & Clinics, Carver College of Medicine, Iowa City, IA 52242, USA. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Mutation, Proto-Oncogene Proteins c-met. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Novartis Pharmaceuticals Corporation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

To assess real-world clinical outcomes with standard therapies for advanced non-small-cell lung cancer (aNSCLC) with METexon14 skipping mutation (METex14).

Methods

In an oncologists-led retrospective review of medical records, data were abstracted and analyzed for patients initiating first-line (1L) systemic therapy after 1 January 2017.

Results

In total 287 aNSCLC patients with METex14, the real-world best overall response rate was 73.4% for capmatinib (n = 146), 68.8% for immunotherapy (IO) monotherapy (n = 48), 52.0% for chemotherapy (CT, n = 30), and 54.8% for IO + CT (n = 63). As compared with capmatinib, patients receiving IO (hazard ratio [HR]: 1.57; 95% CI: 0.77-3.20; p = 0.220), CT (HR: 2.41; 95% CI: 1.19-4.85; p = 0.014) and IO + CT (HR: 2.33; 95% CI: 1.35-4.04; p = 0.003) had higher rates of progression. Further, patients receiving CT (HR: 4.43; 95% CI: 1.54-12.75; p = 0.006) and IO + CT (HR: 3.53, 95% CI: 1.41-8.85; p = 0.007) had higher rates of mortality than patients receiving capmatinib.

Conclusion

The study showed better clinical outcomes with capmatinib than other standard therapies in 1L setting for aNSCLC harboring METex14. Real-world study that investigated the outcomes of different therapies used to treat non-small-cell lung cancer patients with mesenchymal-epithelial transition exon 14 skipping mutationWhat is this article about? A real-world study that investigated clinical outcomes in patients with diagnosis of advanced non-small-cell lung cancer (aNSCLC) with mesenchymal-epithelial transition exon 14 (METex14) skipping–a rare form of genetic mutation–who received treatment with one of the commonly used therapies for this disease: immunotherapy, chemotherapy, immunotherapy + chemotherapy combination and capmatinib, which is a highly selective inhibitor of MET tyrosine kinase protein involved in the growth of cancer cells.What were the results? The study showed that, in general, patients treated with capmatinib as the frontline therapy more frequently achieved a clinical response in the form of complete tumor resolution or tumor shrinkage, had a lower risk of disease worsening and lived longer than patients who were treated with immunotherapy, chemotherapy or immunotherapy + chemotherapy combination.What do the results of the study mean? This study suggests that capmatinib is effective in treating patients with aNSCLC with METex14 skipping who have not been treated with another anticancer therapy previously. It provides evidence to support the use of capmatinib in the frontline setting and may inform clinical decision-making in routine practice.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsMutationProto-Oncogene Proteins c-metHumansFemaleMaleMiddle AgedRetrospective StudiesAgedAntineoplastic Combined Chemotherapy ProtocolsAdultTreatment OutcomeImmunotherapyAged, 80 and overBenzamidesImidazolesTriazines

Stichwörter der Autor:innen

capmatinibmedical chart reviewnon-small-cell lung cancerreal world evidencetreatment effectiveness

Substanzen

Proto-Oncogene Proteins c-metMET protein, humancapmatinibBenzamidesImidazolesTriazines

Autor:innen und Institutionen

  • University of Iowa Hospitals & Clinics, Carver College of Medicine, Iowa City, IA 52242, USA.
  • RTI Health Solutions, Research Triangle Park, NC 27709, USA.
  • Novartis Pharmaceuticals Corporation, East Hanover, NJ 07936, USA.

ORCID-Profile: Muhammad Furqan, Siddharth Karanth, Ravi K Goyal, Beilei Cai, Keith L Davis

Förderung

  • Novartis Pharmaceuticals Corporation

Zitieren

APA

Furqan, M., Karanth, S., Goyal, R. K., Cai, B., Rombi, J., Davis, K. L., Caro, N., & Saliba, T. (2024). Effectiveness of standard treatments in non-small-cell lung cancer with METexon14 skipping mutation: a real-world study. Future Oncology. https://doi.org/10.2217/fon-2023-1064

Vancouver

Furqan M, Karanth S, Goyal RK, Cai B, Rombi J, Davis KL, et al. Effectiveness of standard treatments in non-small-cell lung cancer with METexon14 skipping mutation: a real-world study. Future Oncology. 2024. doi:10.2217/fon-2023-1064

BibTeX
@article{Furqan2024,
  author = {Furqan, Muhammad and Karanth, Siddharth and Goyal, Ravi K and Cai, Beilei and Rombi, Julien and Davis, Keith L and Caro, Nydia and Saliba, Teddy},
  title = {Effectiveness of standard treatments in non-small-cell lung cancer with METexon14 skipping mutation: a real-world study},
  journal = {Future Oncology},
  year = {2024},
  doi = {10.2217/fon-2023-1064}
}
Kostenlos starten →